Marina Yagudaev
Optometrist · Sunny Isles, FLNPI 1447209887
Payments from drug & device makers
Across 184 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$1K
- AbbVie$862
- Bausch & Lomb Americas Inc.$383
- Johnson & Johnson Vision Care, Inc.$362
- Novartis$321
- Alcon$298
- plus $1K from 8 others
What the payments were for
- Food & beverage$4,499100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 52 | $1,074 |
| AbbVie(2 entities) | 39 | $862 |
| Bausch & Lomb Americas Inc. | 18 | $383 |
| Johnson & Johnson Vision Care, Inc. | 8 | $362 |
| Novartis | 16 | $321 |
| Alcon | 16 | $298 |
| Sun Pharmaceutical Industries Inc. | 14 | $268 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $251 |
| Eyevance Pharmaceuticals LLC | 4 | $186 |
| Biotissue Holdings Inc. | 3 | $174 |
| Shire North American Group Inc | 3 | $147 |
| Tarsus Pharmaceuticals, Inc. | 5 | $132 |
| Dompe US, Inc. | 1 | $26 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,499 in reported general payments places this provider in the 85th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 439 | $458,768 |
| XiidraLifitegrast | 65 | $67,462 |
| Cyclosporine | 119 | $35,345 |
| LumiganBimatoprost | 49 | $33,917 |
| XdemvyLotilaner | 13 | $24,372 |
| MieboPerfluorohexyloctane/Pf | 19 | $14,443 |
| TyrvayaVarenicline Tartrate | 17 | $11,283 |
| ZerviateCetirizine Hcl | 16 | $9,906 |
| VyzultaLatanoprostene Bunod | 13 | $6,206 |
| Loteprednol Etabonate | 35 | $5,412 |
| LotemaxLoteprednol Etabonate | 12 | $4,157 |
| Lotemax SmLoteprednol Etabonate | 14 | $3,495 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,429 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 48 | $2,040 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 97 | $1,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $862 | $492,685488 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $383 | $88,11197 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $132 | $24,37213 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax, Lotemax Sm | $251 | $13,06561 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,074 | $11,28317 claims |
| Eyevance Pharmaceuticals LLCZerviate | $186 | $9,90616 claims |
| AlconSimbrinza | $298 | $2,42911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Sunny Isles
- Michael KynnJacksonville$4.5M
- Christine HalodaJacksonville$3.1M
- Bradley GieddWinter Park$2.5M
- Christopher PearsonLongwood$2.5M
- Mark PerryOrlando$1.6M
- Bryan StamJacksonville Beach$1M
- Oksana SovaJacksonville$841K
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$781K
- Jerry RobbenSt Augustine$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.